Skip Navigation

Study shows PARP inhibitor drugs rouse immune system attack on some ovarian cancers

Jean Zhao, PhD
December 11, 2018
Drugs known as PARP inhibitors are transforming the treatment of some ovarian and breast cancers by sabotaging tumor cells’ ability to keep their DNA in working order. In a new study, scientists at Dana-Farber Cancer Institute report that PARP inhibitors can endanger tumor cells on a second front –...
Read Story
  • Explore the Newsroom

    News Releases

    See our news releases about cancer care, cancer research, and cancer treatment by Dana-Farber Cancer Institute doctors and researchers.

    News Coverage

    Get the latest news about Dana-Farber Cancer Institute.

    News Videos

    Watch brief explainer videos focusing on science, research, and advances in cancer, featuring Dana-Farber Cancer Institute doctors and researchers.

    For Journalists

    Dana-Farber welcomes the opportunity to partner with journalists. Find contacts, resources, and more.

    Publications

    Read the latest issues of Dana-Farber publications.

    Insight Blog

    Insight features the latest in cancer care and research news from Dana-Farber.

    Dana-Farber Spotlight

    Sign up to receive Dana-Farber Spotlight, our email newsletter.
    View the current issue
    Subscribe now
    Unsubscribe from mailings
  • View Our Events Calendar

    View Dana-Farber's calendar of events, including nutrition seminars, health and wellness classes, patient education, community outreach and fundraising events, and support groups.

    caregiver support group


    Participants in a caregiver support group